Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axovant Sciences Ltd.

Division of Roivant Sciences GMBH
www.axovant.com

Latest From Axovant Sciences Ltd.

Tech Transfer Roundup: Roivant Taps Research Labs For New Gene Therapies

In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.

Business Strategies Commercial

Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018

The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.

Financing Business Strategies

Axovant Closes Chapter On Failed, Second-Rate Small Molecule Strategy

Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.

Research & Development Neurology

Pipeline Review: Large Potential Overactive Bladder Population Beckons

Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.

Gynecology & Urology Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Roivant Neurosciences Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Roivant Sciences GMBH
  • Senior Management
  • Pavan Cheruvu, MD, CEO
    Gregory M Weinhoff, MD, CFO
    Fraser Wright, PhD, CTO
    Shankar Ramaswamy, MD, SVP, Bus. Dev.
    Gavin Corcoran, MD, EVP, R&D
    Ilise Lombardo, MD, SVP, Clinical Research
  • Contact Info
  • Axovant Sciences Ltd.
    Phone: 203 318 9708
    11-12 St. James’s Square
    Ste. 1, 3rd Fl.
    London, SW1Y 4LB
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register